The expanding Gram-negative antibiotic pipeline offers important new treatment options; however, FDA approval alone does not define a drug’s place in therapy. Clinicians must weigh the clinical problems each agent solves, the strength of the evidence behind it, and what remains unknown before incorporating these therapies into routine practice.